Quick Answer
GALECTIN THERAPEUTICS INC reported Common Stock Shares Outstanding of 65.20 million shares for the year ending 2025.
- GALECTIN THERAPEUTICS INC showed an increase of +3.2% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from GALECTIN THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), GALECTIN THERAPEUTICS INC's Common Stock Shares Outstanding has grown by 512.1%.
- Historical annual values: Fiscal year 2025: 65.20 million shares | Fiscal year 2024: 63.16 million shares | Fiscal year 2023: 61.85 million shares | Fiscal year 2022: 59.43 million shares | Fiscal year 2021: 59.34 million shares | Fiscal year 2020: 57.08 million shares | Fiscal year 2019: 56.89 million shares | Fiscal year 2018: 41.19 million shares | Fiscal year 2017: 35.79 million shares | Fiscal year 2016: 32.91 million shares | Fiscal year 2015: 28.83 million shares | Fiscal year 2014: 22.28 million shares | Fiscal year 2013: 18.39 million shares | Fiscal year 2012: 16.06 million shares | Fiscal year 2011: 12.92 million shares | Fiscal year 2010: 10.65 million shares.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: